http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103479746-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02898911a9c79256ee95420e73ffecfd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-714 |
| filingDate | 2012-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50b85519a4b2d12ccd17857f3fc684e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30096f3d69bfe05443ef6ae60ad93764 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1211f65c69219b4c4397b3af05bcd51 |
| publicationDate | 2015-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103479746-B |
| titleOfInvention | Application of traditional Chinese medicine compound medicinal composition |
| abstract | The invention provides application of raw material medicines for preparing a medicine for assisting reproduction, wherein the raw material medicines comprise 1 to 16 parts of Eucommia ulmoides, 1 to 9 parts of cinnamon, 1 to 16 parts of Chinese angelica and 1 to 16 parts of radix aconiti lateralis preparata in parts by weight. The invention also provides a method for promoting in vitro maturation of an ovarian ovum. The method comprises the following steps: a, taking an immature ovarian ovum; b, placing the immature ovarian ovum in an M199 culture liquid and culturing for 24 hours by adopting a microdrop method to obtain a mature ovarian ovum, wherein the culture liquid contains 2 percent of medicine. The medicine can promote the growth and development of the immature ovarian ovum in vitro and mainly promotes maturation of the ovarian ovum core, and in addition, the cytoskeleton abnormality probability of the mature ovarian ovum is not increased. The medicine can also generate influence on the ovum passing capability of sperms, and can provide reliable basis for clinically preventing and treating the male sperm dysfunction, improving the in vitro fertilization (IVF) success ratio and reducing the use rate of intracytoplasmic sperm injection (ICSI). |
| priorityDate | 2011-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 281.